Soligenix CEO to Present at H.C. Wainwright Global Investment Conference, Highlighting Rare Disease Pipeline

Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The on-demand presentation will be available beginning September 5, 2025, at 7 a.m. ET through the conference platform, with Soligenix management also participating in one-on-one meetings during the event. This presentation matters significantly as it provides institutional investors and analysts direct access to the company's leadership during a pivotal period of clinical development and potential regulatory submissions.

The company's Specialized BioTherapeutics business segment is advancing HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. The expansion of synthetic hypericin (SGX302) into psoriasis represents additional growth potential beyond the initial indication. Development programs in this segment also include the first-in-class innate defense regulator technology, dusquetide (SGX942) for the treatment of inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 in Behçet's Disease.

Soligenix's Public Health Solutions business segment includes development programs for RiVax®, the company's ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola. The segment also includes CiVax™, the vaccine candidate for the prevention of COVID-19 caused by SARS-CoV-2. The development of these vaccine programs incorporates the proprietary heat stabilization platform technology known as ThermoVax®. This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority, demonstrating the strategic importance of these public health initiatives.

The presentation at the H.C. Wainwright conference provides crucial visibility for Soligenix's diverse pipeline addressing significant unmet medical needs in rare diseases and public health threats. Investor conferences of this caliber serve as important platforms for emerging biopharmaceutical companies to articulate their value proposition, clinical progress, and commercialization strategies to the investment community. For Soligenix, this comes at a critical juncture as the company moves toward potential regulatory submissions and commercialization activities for its lead product candidates.